BioCurex’s RECAF blood test potential to monitor cancer recurrence, treatment

BioCurex Inc. (OTCBB:BOCX) today announced that the International Society of Oncology and Biomarkers Congress Scientific Committee has accepted BioCurex's presentation on the RECAF blood test potential to monitor cancer recurrence and treatment. The meeting will be held Sept. 3-8, 2010 in Munich, Germany and is broadly attended by scientists, physicians and biotechnology companies involved in cancer diagnostics.

In addition, Dr. Ricardo Moro, the Chief Executive Officer of BioCurex, has been invited to co-chair a panel discussion on biomarker statistics and make a presentation on the statistical challenges in developing new cancer markers.

"We have previously shown that the RECAF cancer test can be used in a variety of ways including screening and diagnostics," stated Dr. Moro. "In this presentation, our results indicate that the RECAF test could also be used for predicting outcome or monitoring treatment for cancer recurrence. We show that this test has a high sensitivity and specificity in early stages of at least two of the most common types of cancers, prostate and breast, as well as the less frequent ovarian cancer. This strongly suggests that a RECAF positive test might precede the clinical expression of a recurrence and therefore allow the oncologist to detect recurrence and treat patients earlier."

The European Group on Tumor Markers Recommendations (2005) state that markers for breast cancer should be determined every 2–4 months (according to the risk of recurrence) during the initial 5 years after diagnosis, then every 6 months during the next 3 years and at yearly intervals thereafter(1). That represents 15-30 tests per cancer patient during the first 5 years following diagnosis and 2 additional tests per year thereafter. This highlights the importance of an inexpensive, reliable cancer marker test and monitoring tool which BioCurex believes could be fulfilled by its RECAF blood test.

Dr. Moro added, "I am also flattered by the congress organizers' invitation to co-chair a panel of the statistical process of discovering and validating new cancer markers. The concepts I will present have been used at BioCurex in our research and development program relating to our RECAF cancer tests."